Potential Future Targets for Treating Ocular Neovascularization

Ophthalmology Clinics of North America

Volumn 19, Issue 3, 2006, Pages 401-409

  Barouch, Fina C ^a   Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; ANTIINFLAMMATORY AGENT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; BEVACIZUMAB; ENDOSTATIN; ERYTHROPOIETIN; GENISTEIN; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; INTEGRIN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; SEGLITIDE; SOMATOMEDIN B; SOMATOMEDIN C; THROMBOSPONDIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FUNCTIONAL PROTEOMICS; HUMAN; LEUKEMIA; LYMPHOMA; MELANOMA; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA NEOVASCULARIZATION; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SURVIVAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; EYE DISEASES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 33747788728     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2006.05.004     Document Type: Review

References (65)

1. Ciardella A.P., Donsoff I.M., Guyer D.R., et al. Antiangiogenesis agents. Ophthalmol Clin North Am 15 (2002) 453-458
2. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
3. Watanabe D., Suzuma K., Matsui S., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353 (2005) 782-792
4. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
5. Seo M.S., Kwak N., Ozaki H., et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154 (1999) 1743-1753
6. Kwak N., Okamoto N., Wood J.M., et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 3158-3164
7. Saishin Y., Saishin Y., Takahashi K., et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195 (2003) 241-248
8. Schwesinger C., Yee C., Rohan R.M., et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158 (2001) 1161-1172
9. Ohno-Matsui K., Hirose A., Yamamoto S., et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol 160 (2002) 711-719
10. Tolentino M.J., McLeod D.S., Taomoto M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002) 373-385
11. Ozaki H., Hayashi H., Vinores S.A., et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64 (1997) 505-517
12. Campochiaro P.A., and Hackett S.F. Ocular neovascularization: a valuable model system. Oncogene 22 (2003) 6537-6548
13. Okamoto N., Tobe T., Hackett S.F., et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151 (1997) 281-291
14. Grimm C., Wenzel A., Groszer M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8 (2002) 718-724
15. Junk A.K., Mammis A., Savitz S.I., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 99 (2002) 10659-10664
16. Jaquet K., Krause K., Tawakol-Khodai M., et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64 (2002) 326-333
17. Amin R., Puklin J.E., and Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 35 (1994) 3178-3188
18. Reddy V.M., Zamora R.L., and Kaplan H.J. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol 120 (1995) 291-301
19. Sivalingam A., Kenney J., Brown G.C., et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 108 (1990) 869-872
20. Tobe T., Ortega S., Luna J.D., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153 (1998) 1641-1646
21. Ozaki H., Okamoto N., Ortega S., et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol 153 (1998) 757-765
22. Smith L.E., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276 (1997) 1706-1709
23. Poulsen J.E. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 2 (1953) 7-12
24. Wright A.D., Kohner E.M., Oakley N.W., et al. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. BMJ 2 (1969) 346-348
25. Yamagishi S., Nakamura K., Takenaka K., et al. Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B. Microvasc Res 69 (2005) 128-134
26. Joussen A.M., Poulaki V., Tsujikawa A., et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160 (2002) 1683-1693
27. Tait C.R., and Jones P.F. Angiopoietins in tumours: the angiogenic switch. J Pathol 204 (2004) 1-10
28. Nambu H., Nambu R., Oshima Y., et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11 (2004) 865-873
29. Suri C., McClain J., Thurston G., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282 (1998) 468-471
30. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999) 2511-2514
31. Oshima Y., Deering T., Oshima S., et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 199 (2004) 412-417
32. Oshima Y., Oshima S., Nambu H., et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 19 (2005) 963-965
33. Ozaki H., Yu A.Y., Della N., et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40 (1999) 182-189
34. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
35. Wang B., Li H., Yan H., et al. Genistein inhibited hypoxia-inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods Find Exp Clin Pharmacol 27 (2005) 179-184
36. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. Nat Med 8 (2002) 918-921
37. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
38. Friedlander M., Theesfeld C.L., Sugita M., et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 93 (1996) 9764-9769
39. Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 1 (2000) 199-203
40. Morgunova E., Tuuttila A., Bergmann U., et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284 (1999) 1667-1670
41. Liotta L.A., Tryggvason K., Garbisa S., et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980) 67-68
42. De La Paz M.A., Itoh Y., Toth C.A., et al. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci 39 (1998) 1256-1260
43. Steen B., Sejersen S., Berglin L., et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39 (1998) 2194-2200
44. Lambert V., Munaut C., Jost M., et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 161 (2002) 1247-1253
45. Lambert V., Wielockx B., Munaut C., et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17 (2003) 2290-2292
46. Takahashi T., Nakamura T., Hayashi A., et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 130 (2000) 774-781
47. Das A., McLamore A., Song W., et al. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117 (1999) 498-503
48. Cheng L., Rivero M.E., Garcia C.R., et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 17 (2001) 295-304
49. Griffioen A.W. AG-3340 (Agouron Pharmaceuticals Inc). IDrugs 3 (2000) 336-345
50. Blodi BA, Group AS. The angiogenesis inhibitor, prinomastat (AG3340), in the treatment of age-related macular degeneration: study design and baseline characteristics. Presented at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, Florida, April 30-May 5, 2000.
51. Ando A., Yang A., Nambu H., et al. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 62 (2002) 539-544
52. Ando A., Yang A., Mori K., et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 191 (2002) 116-124
53. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
54. Tonini T., Rossi F., and Claudio P.P. Molecular basis of angiogenesis and cancer. Oncogene 22 (2003) 6549-6556
55. Sima J., Zhang S.X., Shao C., et al. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 564 (2004) 19-23
56. Lai C.C., Wu W.C., Chen S.L., et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 42 (2001) 2401-2407
57. Raisler B.J., Berns K.I., Grant M.B., et al. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci U S A 99 (2002) 8909-8914
58. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
59. Marneros A.G., and Olsen B.R. Physiological role of collagen XVIII and endostatin. FASEB J 19 (2005) 716-728
60. Mori K., Ando A., Gehlbach P., et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159 (2001) 313-320
61. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
62. Mori K., Gehlbach P., Yamamoto S., et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1994-2000
63. Mori K., Duh E., Gehlbach P., et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188 (2001) 253-263
64. Mori K., Gehlbach P., Ando A., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43 (2002) 2428-2434
65. Rasmussen H., Chu K.W., Campochiaro P., et al. Clinical protocol: an open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 12 (2001) 2029-2032